The role of the microbiome in CF is emerging in the context of the broader concept of the gut–lung axis [187]; the study of the effects of the CFTR-modulating therapies on the microbiome are at their beginning, but some evidence is emerging. Here, CFTR is linked to cystic fibrosis.